These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 38573411)

  • 1. Parametric net influx rate imaging of
    Yin H; Liu G; Mao W; Lv J; Yu H; Cheng D; Cai L; Shi H
    Ann Nucl Med; 2024 Jul; 38(7):483-492. PubMed ID: 38573411
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Parametric Net Influx Rate Images of
    Ilan E; Sandström M; Velikyan I; Sundin A; Eriksson B; Lubberink M
    J Nucl Med; 2017 May; 58(5):744-749. PubMed ID: 27789716
    [No Abstract]   [Full Text] [Related]  

  • 3. Quantitative and qualitative intrapatient comparison of 68Ga-DOTATOC and 68Ga-DOTATATE: net uptake rate for accurate quantification.
    Velikyan I; Sundin A; Sörensen J; Lubberink M; Sandström M; Garske-Román U; Lundqvist H; Granberg D; Eriksson B
    J Nucl Med; 2014 Feb; 55(2):204-10. PubMed ID: 24379222
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Does whole-body Patlak
    Fahrni G; Karakatsanis NA; Di Domenicantonio G; Garibotto V; Zaidi H
    Eur Radiol; 2019 Sep; 29(9):4812-4821. PubMed ID: 30689031
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor-to-Blood Ratio for Assessment of Somatostatin Receptor Density in Neuroendocrine Tumors Using
    Ilan E; Velikyan I; Sandström M; Sundin A; Lubberink M
    J Nucl Med; 2020 Feb; 61(2):217-221. PubMed ID: 31302632
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of parametric imaging and SUV imaging with [
    Chen R; Ng YL; Yang X; Zhu Y; Li L; Zhao H; Zhou Y; Huang G; Liu J
    Eur J Nucl Med Mol Imaging; 2024 Jan; 51(2):568-580. PubMed ID: 37792025
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MIB-1 Index-Stratified Assessment of Dual-Tracer PET/CT with
    Sampathirao N; Basu S
    J Nucl Med Technol; 2017 Mar; 45(1):34-41. PubMed ID: 28154019
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 68Ga-DOTATATE PET/CT, 99mTc-HYNIC-octreotide SPECT/CT, and whole-body MR imaging in detection of neuroendocrine tumors: a prospective trial.
    Etchebehere EC; de Oliveira Santos A; Gumz B; Vicente A; Hoff PG; Corradi G; Ichiki WA; de Almeida Filho JG; Cantoni S; Camargo EE; Costa FP
    J Nucl Med; 2014 Oct; 55(10):1598-604. PubMed ID: 25168627
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Can we differentiate histologic subtypes of neuroendocrine tumour liver metastases at a single phase contrast-enhanced CT-correlation with Ga-68 DOTATATE PET/CT findings.
    Gulpinar B; Peker E; Soydal C; Araz M; Elhan AH
    Br J Radiol; 2020 Feb; 93(1106):20190735. PubMed ID: 31922897
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparison of 68Ga-DOTATATE and 18F-FDG PET/CT in pulmonary neuroendocrine tumors.
    Kayani I; Conry BG; Groves AM; Win T; Dickson J; Caplin M; Bomanji JB
    J Nucl Med; 2009 Dec; 50(12):1927-32. PubMed ID: 19910422
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of ⁶⁸Ga-DOTATATE and ⁶⁸Ga-DOTANOC PET/CT imaging in the same patient group with neuroendocrine tumours.
    Kabasakal L; Demirci E; Ocak M; Decristoforo C; Araman A; Ozsoy Y; Uslu I; Kanmaz B
    Eur J Nucl Med Mol Imaging; 2012 Aug; 39(8):1271-7. PubMed ID: 22526963
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical feasibility and impact of fully automated multiparametric PET imaging using direct Patlak reconstruction: evaluation of 103 dynamic whole-body
    Dias AH; Pedersen MF; Danielsen H; Munk OL; Gormsen LC
    Eur J Nucl Med Mol Imaging; 2021 Mar; 48(3):837-850. PubMed ID: 32894338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of somatostatin receptor expressing tumor volume calculated from
    Toriihara A; Baratto L; Nobashi T; Park S; Hatami N; Davidzon G; Kunz PL; Iagaru A
    Eur J Nucl Med Mol Imaging; 2019 Oct; 46(11):2244-2251. PubMed ID: 31350603
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation of 68Ga-DOTATATE uptake on PET/CT with pathologic features of cellular proliferation in neuroendocrine neoplasms.
    Karls S; Gold R; Kravets S; Wang Y; Cheng S; Perez K; Chan J; Jacene H
    Ann Nucl Med; 2021 Sep; 35(9):1066-1077. PubMed ID: 34146243
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors.
    Wild D; Bomanji JB; Benkert P; Maecke H; Ell PJ; Reubi JC; Caplin ME
    J Nucl Med; 2013 Mar; 54(3):364-72. PubMed ID: 23297077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 68Ga-DOTATOC versus 68Ga-DOTATATE PET/CT in functional imaging of neuroendocrine tumors.
    Poeppel TD; Binse I; Petersenn S; Lahner H; Schott M; Antoch G; Brandau W; Bockisch A; Boy C
    J Nucl Med; 2011 Dec; 52(12):1864-70. PubMed ID: 22072704
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Direct inference of Patlak parametric images in whole-body PET/CT imaging using convolutional neural networks.
    Zaker N; Haddad K; Faghihi R; Arabi H; Zaidi H
    Eur J Nucl Med Mol Imaging; 2022 Oct; 49(12):4048-4063. PubMed ID: 35716176
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Head-to-Head Comparison of
    Johnbeck CB; Knigge U; Loft A; Berthelsen AK; Mortensen J; Oturai P; Langer SW; Elema DR; Kjaer A
    J Nucl Med; 2017 Mar; 58(3):451-457. PubMed ID: 27660147
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 68Ga-DOTATATE PET/CT Interobserver Agreement for Neuroendocrine Tumor Assessment: Results of a Prospective Study on 50 Patients.
    Fendler WP; Barrio M; Spick C; Allen-Auerbach M; Ambrosini V; Benz M; Bluemel C; Grewal RK; Lapa C; Miederer M; Nicolas G; Schuster T; Czernin J; Herrmann K
    J Nucl Med; 2017 Feb; 58(2):307-311. PubMed ID: 27539839
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Defining the optimal segmentation method for measuring somatostatin receptor expressing tumor volume on 68 Ga-DOTATATE positron emission tomography/computed tomography to predict prognosis in patients with gastroenteropancreatic neuroendocrine tumors.
    Filizoglu N; Ozguven S; Akin Telli T; Ones T; Dede F; Turoglu HT; Erdil TY
    Nucl Med Commun; 2024 Aug; 45(8):736-744. PubMed ID: 38745508
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.